1189924-28-4
Chemical Structure
Guanfacine-13C,15N3
- CAS No.: 1189924-28-4
- Formula:C813CH9Cl215N3O
- Molecular Weight:250.07
IUPAC Name: N-(carbamimidoyl-13C-15N2)-2-(2,6-dichlorophenyl)acetamide-15N
InChIKey: INJOMKTZOLKMBF-DATIIYMNSA-N
SMILES: O=C([15NH][13C]([15NH2])=[15NH])CC1=C(Cl)C=CC=C1Cl
Biological Activity: Guanfacine-13C,15N3 is the 13C and 15N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Guanfacine-13C,15N3 | Guanfacine-13C,15N3 is the 13C and 15N labeled Guanfacine. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Guanfacine-15N13,13C2 | Guanfacine-15N3,13C2 is 15N and 13C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Guanfacine | 99.85% | Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Amy F T Arnsten, et al. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012 Mar;85(1):45-58. Epub 2012 Mar 29. [Content Brief]
- [3]. P. A. Van Zwieten, et al. The pharmacology of centrally acting antihypertensive drugs. Br J Clin Pharmacol. 1983 15(Suppl 4): 455S–462S.
- [4]. Min Wang, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007 Apr 20129(2):397-410. [Content Brief]
